Koers Novavax, Inc. Nasdaq
Aandelen
US6700021040
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 846 mln. 791 mln. | Omzet 2025 * | 986 mln. 923 mln. | Marktkapitalisatie | 572 mln. 535 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -112 mln. -105 mln. | Nettowinst (verlies) 2025 * | -90 mln. -84,17 mln. | EV/omzet 2024 * | 0,07 x |
Nettoliquiditeiten 2024 * | 510 mln. 477 mln. | Nettoliquiditeiten 2025 * | 482 mln. 451 mln. | EV/omzet 2025 * | 0,09 x |
K/w-verhouding 2024 * |
-5,66
x | K/w-verhouding 2025 * |
-103
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,33% |
Recentste transcriptie over Novavax, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-23 |
John Trizzino
PSD | President | 64 | 10-03-14 |
James Kelly
DFI | Director of Finance/CFO | 58 | 16-08-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 29-10-22 |
Gregg Alton
BRD | Director/Board Member | 58 | 01-11-20 |
David Mott
BRD | Director/Board Member | 58 | 16-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |